CorAssist is a medical device company developing novel solutions for Congestive Heart Failure (CHF). The company’s first product, the ImCardia, is a mechanical cardiac Extraventricular Assist Device, aiming to improve the quality of life of patients suffering from Diastolic Dysfunction. CorAssist proprietary technology enables the first off-pump surgical implantation of a device, addressing Diastolic Heart Failure (DHF). The ImCardia has no external source of energy and is incorporated onto the heart muscle, allowing the left ventricle (LV) to fill with lower diastolic pressures. As DHF is associated with severe pulmonary symptoms and dysfunction, cost of the disease generates a dramatic impact on the healthcare system. More than 1.5 million people in the US suffer from DHF, and CorAssist is looking to win a significant share of this important emerging market.
    Fund III  

Neomedia - Keepin' it simple!